These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31436583)

  • 1. Role of type I interferons and innate immunity in systemic sclerosis: unbalanced activities on distinct cell types?
    Barrat FJ; Lu TT
    Curr Opin Rheumatol; 2019 Nov; 31(6):569-575. PubMed ID: 31436583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I interferon dysregulation in Systemic Sclerosis.
    Skaug B; Assassi S
    Cytokine; 2020 Aug; 132():154635. PubMed ID: 30685202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature.
    Lande R; Mennella A; Palazzo R; Pietraforte I; Stefanantoni K; Iannace N; Butera A; Boirivant M; Pica R; Conrad C; Chizzolini C; Riccieri V; Frasca L
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32707718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting interferons as a strategy for systemic sclerosis treatment.
    Ciechomska M; Skalska U
    Immunol Lett; 2018 Mar; 195():45-54. PubMed ID: 29106987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low RUNX3 expression alters dendritic cell function in patients with systemic sclerosis and contributes to enhanced fibrosis.
    Affandi AJ; Carvalheiro T; Ottria A; Broen JC; Bossini-Castillo L; Tieland RG; Bon LV; Chouri E; Rossato M; Mertens JS; Garcia S; Pandit A; de Kroon LM; Christmann RB; Martin J; van Roon JA; Radstake TR; Marut W
    Ann Rheum Dis; 2019 Sep; 78(9):1249-1259. PubMed ID: 31126957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I IFNs Regulate Inflammation, Vasculopathy, and Fibrosis in Chronic Cutaneous Graft-versus-Host Disease.
    Delaney TA; Morehouse C; Brohawn PZ; Groves C; Colonna M; Yao Y; Sanjuan M; Coyle AJ
    J Immunol; 2016 Jul; 197(1):42-50. PubMed ID: 27226090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel insights on the role of the innate immune system in systemic sclerosis.
    York MR
    Expert Rev Clin Immunol; 2011 Jul; 7(4):481-9. PubMed ID: 21790291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis.
    Lei L; Zhao C; Qin F; He ZY; Wang X; Zhong XN
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):14-22. PubMed ID: 26750756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early inflammatory players in cutanous fibrosis.
    Raker V; Haub J; Stojanovic A; Cerwenka A; Schuppan D; Steinbrink K
    J Dermatol Sci; 2017 Sep; 87(3):228-235. PubMed ID: 28655471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts.
    Raschi E; Chighizola CB; Cesana L; Privitera D; Ingegnoli F; Mastaglio C; Meroni PL; Borghi MO
    Arthritis Res Ther; 2018 Aug; 20(1):187. PubMed ID: 30157947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Regulation of Skin Fibrosis in Systemic Sclerosis by Extracellular ATP via P2Y
    Perera LMB; Sekiguchi A; Uchiyama A; Uehara A; Fujiwara C; Yamazaki S; Yokoyama Y; Ogino S; Torii R; Hosoi M; Ishikawa O; Motegi SI
    J Invest Dermatol; 2019 Apr; 139(4):890-899. PubMed ID: 30404019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
    Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrosis and immune dysregulation in systemic sclerosis.
    Chizzolini C; Brembilla NC; Montanari E; Truchetet ME
    Autoimmun Rev; 2011 Mar; 10(5):276-81. PubMed ID: 20863906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis.
    Bhattacharyya S; Wang W; Tamaki Z; Shi B; Yeldandi A; Tsukimi Y; Yamasaki M; Varga J
    Front Immunol; 2018; 9():2434. PubMed ID: 30405628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppressive Regulation by MFG-E8 of Latent Transforming Growth Factor β-Induced Fibrosis via Binding to αv Integrin: Significance in the Pathogenesis of Fibrosis in Systemic Sclerosis.
    Fujiwara C; Uehara A; Sekiguchi A; Uchiyama A; Yamazaki S; Ogino S; Yokoyama Y; Torii R; Hosoi M; Suto C; Tsunekawa K; Murakami M; Ishikawa O; Motegi SI
    Arthritis Rheumatol; 2019 Feb; 71(2):302-314. PubMed ID: 30175895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From microvasculature to fibroblasts: Contribution of anti-endothelial cell antibodies in systemic sclerosis.
    Corallo C; Franci B; Lucani B; Montella A; Chirico C; Gonnelli S; Nuti R; Giordano N
    Int J Immunopathol Pharmacol; 2015 Mar; 28(1):93-103. PubMed ID: 25816411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis.
    Artlett CM; Sassi-Gaha S; Rieger JL; Boesteanu AC; Feghali-Bostwick CA; Katsikis PD
    Arthritis Rheum; 2011 Nov; 63(11):3563-74. PubMed ID: 21792841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.
    Noda S; Asano Y; Nishimura S; Taniguchi T; Fujiu K; Manabe I; Nakamura K; Yamashita T; Saigusa R; Akamata K; Takahashi T; Ichimura Y; Toyama T; Tsuruta D; Trojanowska M; Nagai R; Sato S
    Nat Commun; 2014 Dec; 5():5797. PubMed ID: 25504335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.